Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies
Oncology immunotherapy has been a significant advancement in cancer treatment and involves harnessing and redirecting a patient’s immune response towards their own tumour. Specific recognition and elimination of tumour cells was first proposed over a century ago with Paul Erlich’...
Main Authors: | Rebecca C. Abbott, Ryan S. Cross, Misty R. Jenkins |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/2/515 |
Similar Items
-
Tuning the performance of CAR T cell immunotherapies
by: Noah H. Richardson, et al.
Published: (2019-11-01) -
Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment
by: Olaf Oberschmidt, et al.
Published: (2017-06-01) -
Antigen-specific T cell activation independently of the MHC: chimeric antigen receptor (CAR)-redirected T cells.
by: Hinrich eAbken, et al.
Published: (2013-11-01) -
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
by: Rohtesh S. Mehta, et al.
Published: (2018-02-01) -
Chimeric Antigen Receptor-Engineered T Cells in Tumor Immunotherapy: From Bench to Beside
by: Peng WANG
Published: (2017-06-01)